News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
638,674 Results
Type
Article (30682)
Company Profile (179)
Press Release (607809)
Multimedia
Podcasts (85)
Webinars (9)
Section
Business (206785)
Career Advice (1573)
Deals (31032)
Drug Delivery (102)
Drug Development (76372)
Employer Resources (94)
FDA (15275)
Job Trends (12000)
News (308948)
Policy (26525)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (8)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (1902)
Accelerated approval (59)
ADA (35)
Adcomms (23)
Allergies (167)
Alliances (42320)
ALS (210)
Alzheimer's disease (1658)
Antibody-drug conjugate (ADC) (550)
Approvals (15947)
Artificial intelligence (623)
ASCO (295)
Autoimmune disease (378)
Automation (48)
Bankruptcy (315)
Belgium (3)
Best Places to Work (9599)
BIO (58)
Biologics (12)
BIOSECURE Act (15)
Biosimilars (220)
BioSpace Insights (76)
Biotechnology (120)
Bispecific (1)
Bladder cancer (207)
Brain cancer (70)
Breast cancer (775)
Cancer (6214)
Cardiovascular disease (494)
Career advice (1350)
Career pathing (39)
CAR-T (344)
CDC (45)
CDMO (105)
Celiac Disease (3)
Cell therapy (889)
Cervical cancer (52)
Clinical research (68436)
Collaboration (1942)
Commercialization (9)
Company closure (5)
Compensation (1671)
Complete response letters (69)
COVID-19 (2134)
CRISPR (110)
C-suite (1148)
Cystic fibrosis (146)
Data (8610)
Decentralized trials (1)
Denatured (10)
Depression (177)
Dermatology (111)
Diabetes (598)
Diagnostics (5905)
Digital health (49)
Diversity (6)
Diversity, equity & inclusion (25)
Drug discovery (307)
Drug pricing (129)
Drug shortages (12)
Duchenne muscular dystrophy (287)
Earnings (89683)
Editorial (59)
Employer branding (9)
Employer resources (92)
Events (106049)
Executive appointments (975)
FDA (19399)
Fibrodysplasia Ossificans Progressiva (11)
Fragile X (1)
Friedreich's ataxia (21)
Frontotemporal dementia (36)
Funding (1662)
Gene editing (234)
Generative AI (45)
Gene therapy (704)
GLP-1 (889)
Government (3053)
Grass and pollen (6)
Guidances (396)
Healthcare (15037)
Hematology (173)
HIV (90)
Huntington's disease (59)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (117)
Immunology and inflammation (280)
Immuno-oncology (120)
Indications (230)
Infectious disease (2473)
Inflammatory bowel disease (215)
Inflation Reduction Act (13)
Influenza (130)
Intellectual property (309)
Interviews (308)
IPO (14956)
IRA (40)
Job creations (2753)
Job search strategy (1079)
JPM (41)
Kidney cancer (22)
Labor market (80)
Layoffs (414)
Leadership (36)
Legal (6514)
Licensing (25)
Liver cancer (90)
Longevity (29)
Lung cancer (885)
Lymphoma (469)
Machine learning (47)
Management (34)
Manufacturing (963)
Marketing (11)
MASH (191)
Medical affairs (3)
Medical device (11950)
Medtech (12153)
Mergers & acquisitions (17291)
Metabolic disorders (1436)
mRNA (207)
Multiple sclerosis (189)
Multispecific (1)
NASH (20)
Netherlands (1)
Neurodegenerative disease (458)
Neuropsychiatric disorders (98)
Neuroscience (3237)
Neurotech (1)
NextGen: Class of 2026 (4902)
Non-profit (2642)
Now hiring (15)
Obesity (613)
Opinion (230)
Ovarian cancer (231)
Pain (275)
Pancreatic cancer (354)
Parkinson's disease (374)
Partnered (30)
Patents (623)
Patient advocacy (1)
Patient recruitment (927)
Patient selection (2)
Peanut (55)
People (50182)
Peptides (5)
Pharmaceutical (39)
Pharmacy benefit managers (16)
Phase 1 (21973)
Phase 2 (29912)
Phase 3 (22065)
Pipeline (10890)
Policy (225)
Postmarket research (2313)
Preclinical (8679)
Press Release (53)
Prostate cancer (319)
Psychedelics (55)
Radiopharmaceuticals (301)
Rare diseases (1170)
Real estate (4496)
Recruiting (45)
Regenerative medicine (1)
Regulatory (22661)
Reports (43)
Research institute (1720)
Resumes & cover letters (266)
Rett syndrome (49)
RNA editing (21)
RSV (84)
Schizophrenia (179)
Series A (288)
Series B (220)
Service/supplier (7)
Sickle cell disease (119)
Special edition (24)
Spinal muscular atrophy (174)
Sponsored (31)
Startups (3047)
Stomach cancer (20)
Supply chain (92)
Tariffs (61)
The Weekly (74)
Vaccines (962)
Venture capital (89)
Weight loss (373)
Women's health (130)
Worklife (14)
Date
Today (72)
Last 7 days (491)
Last 30 days (2046)
Last 365 days (27108)
2026 (19285)
2025 (26612)
2024 (30812)
2023 (35175)
2022 (44533)
2021 (48005)
2020 (44440)
2019 (35535)
2018 (26652)
2017 (26750)
2016 (25526)
2015 (31848)
2014 (27182)
2013 (22609)
2012 (24700)
2011 (25034)
2010 (24854)
Location
Africa (612)
Alabama (92)
Alaska (7)
Arizona (361)
Arkansas (14)
Asia (33550)
Australia (5120)
California (14319)
Canada (3773)
China (1476)
Colorado (588)
Connecticut (571)
Delaware (427)
Europe (65197)
Florida (2112)
Georgia (451)
Hawaii (3)
Idaho (52)
Illinois (1022)
India (85)
Indiana (552)
Iowa (26)
Japan (592)
Kansas (122)
Kentucky (40)
Louisiana (51)
Maine (90)
Maryland (1617)
Massachusetts (9915)
Michigan (358)
Minnesota (726)
Mississippi (7)
Missouri (121)
Montana (29)
Nebraska (26)
Nevada (142)
New Hampshire (73)
New Jersey (3600)
New Mexico (23)
New York (3544)
North Carolina (1754)
North Dakota (8)
Northern California (7330)
Ohio (386)
Oklahoma (19)
Oregon (31)
Pennsylvania (2688)
Puerto Rico (29)
Rhode Island (44)
South America (853)
South Carolina (84)
South Dakota (2)
Southern California (5763)
Tennessee (171)
Texas (2311)
United States (48750)
Utah (424)
Vermont (1)
Virginia (274)
Washington D.C. (57)
Washington State (1095)
West Virginia (2)
Wisconsin (115)
Wyoming (2)
638,674 Results for "first databank inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MustGrow Receives First Milestone Payment from Bayer AG
• Bayer AG has paid MustGrow the first development milestone payment. • The MustGrow / Bayer AG License and Collaboration Agreement, signed in December 2023, covers soil applications of MustGrow’s mustard-based biocontrol technologies in Europe, Middle East and Africa.
August 21, 2026
·
6 min read
Approvals
FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease
Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, which intends to leverage the foothold for more approvals in rare neurodegenerative diseases, including Angelman syndrome.
September 3, 2026
·
5 min read
·
Heather McKenzie
Press Releases
Medical Care Technologies Inc. (OTCID:MDCE) Melanoma Scan Beta Seeks First Volunteer Cohorts for Human-Submitted Image Dataset Testing
August 31, 2026
·
3 min read
Press Releases
Nanochon Performs First Case in the Chondrograft™ First-in-Human Clinical Study
September 8, 2026
·
3 min read
Press Releases
Medical Care Technologies Inc. (OTCID:MDCE) Activates Volunteer Intake for Melanoma Scan Beta After Launching First Human-Submitted Dataset Initiative
September 4, 2026
·
3 min read
Press Releases
Exagen Inc. Reports First Quarter 2026 Results
May 11, 2026
·
10 min read
Press Releases
Progyny, Inc. Announces First Quarter 2026 Results
May 8, 2026
·
28 min read
Press Releases
DIESSE Diagnostica Senese Establishes DIESSE Inc., Its First Direct Subsidiary in the United States
July 13, 2026
·
3 min read
Press Releases
Penumbra, Inc. Reports First Quarter 2026 Financial Results
May 7, 2026
·
6 min read
FDA
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis’ Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.
September 9, 2026
·
1 min read
·
Jef Akst
1 of 63,868
Next
